Perceptive Informatics Enhances Medical Imaging Reporting To Facilitate Greater Data-Driven Trial Insights
BOSTON, April 13 /PRNewswire-FirstCall/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has expanded its leading medical imaging capabilities with an enhanced reporting solution. Perceptive is among the first to offer a reporting solution that incorporates the industry-standard performance metrics for imaging core labs, as defined by the Metrics Champion Consortium (MCC), allowing trial sponsors to track progress against MCC criteria.
"The various stakeholder groups within imaging-based clinical programs have diverse informational needs, which Perceptive is committed to meeting by continually enhancing our technology capabilities. Clients can benefit from our powerful reporting solution which has been designed to provide high quality data to enable greater insights into trial progress and support faster execution," said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics.
One of the key features of Perceptive's enhanced reporting solution is a dashboard that presents high level imaging performance metrics to convey vital study information at a glance. The dashboard allows study leaders to view snapshots of study progress for rapid analysis of data. User-friendly graphical displays provide visibility into key performance indicators (KPIs) and enable centralized access to imaging metrics for multiple trials and cross-study program monitoring.
The imaging reporting solution includes a comprehensive suite of online interactive reports. The reports deliver data on study progress with interactive functionality that allows users to drill down on various aspects of tracking performance.
The Medical Imaging Group of Perceptive Informatics offers a full range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, neurology, rheumatology, cardiology, and endocrinology. Perceptive's medical imaging technologies are fully validated and in compliance with regulatory guidelines.
Note: Experts from Perceptive Informatics, a sponsor of The Metrics Champion Consortium (MCC), participate in several MCC working groups. The MCC is an open, multidisciplinary, non-profit organization comprised of biotechnology, pharmaceutical and service provider organizations. The mission of MCC is to develop, through a collaborative process, performance metrics within the biotechnology and pharmaceutical industry with the intent to jointly encourage performance improvement, effectiveness, efficiency, and appropriate levels of controls for both sponsors and service providers in support of the drug development process.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 9,200 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings, including the anticipated restructuring charge of approximately $30 million over the second and third quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2009 as filed with the SEC on February 5, 2010, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
Senior Director of Public Relations
Gene Carozza/Kim Baker
SOURCE PAREXEL International Corporation
Back to top